# Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

> **NCT04629170** · PHASE1 · COMPLETED · sponsor: **Synlogic** · enrollment: 77 (actual)

## Conditions studied

- Healthy
- Enteric Hyperoxaluria

## Interventions

- **DRUG:** SYNB8802
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04629170
- **Lead sponsor:** Synlogic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-01-17
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629170, "Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04629170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*